Stock A039200 OSCOTEC INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Oscotec Inc.

Equities

A039200

KR7039200001

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-07-16 pm EDT 		5-day change 1st Jan Change
42,600 KRW -1.84% Intraday chart for Oscotec Inc. -1.16% +84.82%
Feb. 23 Oscotec/Adel Initiates First-In-Human Dosing in Ph1 of Anti-Mtbr Tau Antibody Adel-Y01 in Alzheimer's Disease CI
2023 Oscotec Inc. and ADEL Inc. Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease CI

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
OSCOTEC INC. Stock Oscotec Inc.
+84.82% 1.2B -
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+34.09% 10.31B
A-
YUHAN CORPORATION Stock Yuhan Corporation
+40.41% 5.23B
B-
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-15.24% 4.62B
A-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+11.62% 3.52B -
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+26.25% 2.31B - -
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-38.78% 1.78B
C-
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-44.54% 1.69B -
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B - -
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+0.73% 1.59B
D+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. A039200 Stock
  4. Ratings Oscotec Inc.